About AMAG Pharmaceuticals (NASDAQ:AMAG)
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
Industry, Sector and Symbol
Trailing P/E Ratio-3.39505574064243
Forward P/E Ratio-5.94
Sales & Book Value
Annual Sales$609.95 million
Price / Sales1.08
Price / CashN/A
Book Value$22.34 per share
Price / Book0.86
Return on Equity0.96%
Return on Assets0.39%
AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions
What is AMAG Pharmaceuticals' stock symbol?
AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."
How were AMAG Pharmaceuticals' earnings last quarter?
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced its quarterly earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.68. The specialty pharmaceutical company had revenue of $158.30 million for the quarter, compared to analysts' expectations of $158.84 million. AMAG Pharmaceuticals had a negative net margin of 32.66% and a positive return on equity of 0.96%. AMAG Pharmaceuticals's revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.31) earnings per share. View AMAG Pharmaceuticals' Earnings History.
When will AMAG Pharmaceuticals make its next earnings announcement?
Where is AMAG Pharmaceuticals' stock going? Where will AMAG Pharmaceuticals' stock price be in 2018?
11 analysts have issued 1 year price targets for AMAG Pharmaceuticals' stock. Their predictions range from $17.00 to $45.00. On average, they anticipate AMAG Pharmaceuticals' share price to reach $24.20 in the next twelve months. View Analyst Ratings for AMAG Pharmaceuticals.
What are Wall Street analysts saying about AMAG Pharmaceuticals stock?
Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, "Makena autoinjector moving to launch pad. On today’s call, management commented that the autoinjector would be launched by the end of March. Pre- launch activities include the critical element of providing patient access to the drug. We believe it possible that the switch to the autoinjector could be facilitated through modulating the Makena vial (IM administration) inventory." (2/27/2018)
- 2. According to Zacks Investment Research, "AMAG reported earnings of $1.57 in the third quarter of 2017 as against the Zacks Consensus Estimate of a loss. However, the company missed the same on revenues. AMAG lowered its total revenue guidance for 2017. Furthermore, the termination of the licensing agreement with Takeda for Feraheme in ex-U.S. territories was a major setback for the company. So far this year, AMAG’s shares have underperformed the industry. Nevertheless, the company is working towards label expansion of Feraheme, and potential approval and launch of the Makena subcutaneous auto-injector (SQ) AMAG also remains focused on expanding Makena’s label further in a bid to increase its market share." (11/8/2017)
Who are some of AMAG Pharmaceuticals' key competitors?
Some companies that are related to AMAG Pharmaceuticals include PTC Therapeutics (PTCT), Epizyme (EPZM), Pacira Pharmaceuticals (PCRX), G1 Therapeutics (GTHX), CytomX Therapeutics (CTMX), Mallinckrodt (MNK), Intra-Cellular Therapies (ITCI), Apellis Pharmaceuticals (APLS), Assembly Biosciences (ASMB), Myovant Sciences (MYOV), Cellectis (CLLS), Dynavax Technologies (DVAX), DBV Technologies (DBVT), Wave Life Sciences (WVE), Revance Therapeutics (RVNC), Genomic Health (GHDX), ARMO BioSciences (ARMO) and Acorda Therapeutics (ACOR).
Who are AMAG Pharmaceuticals' key executives?
AMAG Pharmaceuticals' management team includes the folowing people:
- Gino Santini, Independent Chairman of the Board (Age 60)
- William K. Heiden, President, Chief Executive Officer, Director (Age 57)
- Edward Myles CPA, Chief Financial Officer, Senior Vice President - Finance, Treasurer (Age 45)
- Nathan McBride, Senior Vice President - Innovation Architects, Chief Information Officer
- Joseph D. Vittiglio, Senior Vice President - Legal Affairs, Technical Operations and Quality, General Counsel, Secretary (Age 45)
- Tony Casciano, Senior Vice President of Sales and Marketing - Hematology and Oncology business
- Paul Williams, Senior Vice President - Sales and Marketing, Women’s Health
- Elizabeth Bolgiano, Senior Vice President of Human Resources
- Julie Krop M.D., Chief Medical Officer and Senior Vice President - Clinical Development and Regulatory Affairs (Age 51)
- Scott T. McMillan Ph.D., Senior Vice President - Quality and Technical Operations
Has AMAG Pharmaceuticals been receiving favorable news coverage?
Media stories about AMAG stock have trended positive on Saturday, according to Accern. The research firm identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a coverage optimism score of 0.38 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 46.08 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are AMAG Pharmaceuticals' major shareholders?
AMAG Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Palo Alto Investors LLC (9.88%), LSV Asset Management (3.17%), Renaissance Technologies LLC (2.41%), Robeco Institutional Asset Management B.V. (2.20%), Millennium Management LLC (1.82%) and Acadian Asset Management LLC (1.41%). Company insiders that own AMAG Pharmaceuticals stock include Joseph Vittiglio and Julie Krop. View Institutional Ownership Trends for AMAG Pharmaceuticals.
Which major investors are selling AMAG Pharmaceuticals stock?
AMAG stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Acadian Asset Management LLC, LSV Asset Management, Gotham Asset Management LLC, Alambic Investment Management L.P., Guggenheim Capital LLC, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp and TIAA CREF Investment Management LLC. Company insiders that have sold AMAG Pharmaceuticals company stock in the last year include Joseph Vittiglio and Julie Krop. View Insider Buying and Selling for AMAG Pharmaceuticals.
Which major investors are buying AMAG Pharmaceuticals stock?
AMAG stock was bought by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Renaissance Technologies LLC, Robeco Institutional Asset Management B.V., Spark Investment Management LLC, Amundi Pioneer Asset Management Inc., Palo Alto Investors LLC, Arizona State Retirement System and Fox Run Management L.L.C.. View Insider Buying and Selling for AMAG Pharmaceuticals.
How do I buy shares of AMAG Pharmaceuticals?
Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AMAG Pharmaceuticals' stock price today?
One share of AMAG stock can currently be purchased for approximately $19.25.
How big of a company is AMAG Pharmaceuticals?
AMAG Pharmaceuticals has a market capitalization of $668.14 million and generates $609.95 million in revenue each year. The specialty pharmaceutical company earns $-199,220,000.00 in net income (profit) each year or ($5.67) on an earnings per share basis. AMAG Pharmaceuticals employs 762 workers across the globe.
How can I contact AMAG Pharmaceuticals?
AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]
MarketBeat Community Rating for AMAG Pharmaceuticals (AMAG)MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
AMAG Pharmaceuticals (NASDAQ:AMAG) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||2.18||2.27||2.13||2.15|
|Ratings Breakdown: ||0 Sell Rating(s)|
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
11 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$24.20||$22.11||$23.58||$28.45|
|Price Target Upside: ||25.71% upside||59.07% upside||69.06% upside||52.16% upside|
AMAG Pharmaceuticals (NASDAQ:AMAG) Consensus Price Target History
AMAG Pharmaceuticals (NASDAQ:AMAG) Analyst Ratings History
(Data available from 3/24/2016 forward)
AMAG Pharmaceuticals (NASDAQ:AMAG) Earnings History and Estimates Chart
AMAG Pharmaceuticals (NASDAQ AMAG) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/27/2018||Q4 2017||($0.58)||$0.10||$158.84 million||$158.30 million||View||N/A|
|11/2/2017||Q3 2017||($0.04)||$1.57||$166.83 million||$153.74 million||View||N/A|
|8/3/2017||Q2 2017||($0.58)||($0.40)||$158.83 million||$158.39 million||View||Listen|
|5/2/2017||Q1 2017||$0.09||($1.06)||$150.32 million||$139.47 million||View||Listen|
|2/14/2017||Q416||$0.24||($0.31)||$155.12 million||$151.60 million||View||Listen|
|11/3/2016||Q316||$1.50||$1.78||$141.65 million||$143.80 million||View||Listen|
|8/9/2016||Q216||$1.20||$1.45||$128.52 million||$127.40 million||View||Listen|
|5/3/2016||Q116||$1.11||$0.94||$124.83 million||$117.60 million||View||Listen|
|2/17/2016||Q415||$1.16||$1.12||$120.13 million||$108.70 million||View||Listen|
|11/3/2015||Q315||$1.21||($0.62)||$113.88 million||$103.50 million||View||Listen|
|7/23/2015||Q215||$0.75||$1.12||$94.05 million||$123.90 million||View||Listen|
|5/5/2015||Q115||$1.04||$1.11||$84.66 million||$89.50 million||View||Listen|
|2/9/2015||Q4 2014||$0.30||$0.04||$53.94 million||$53.25 million||View||N/A|
|10/30/2014||Q314||($0.08)||$0.06||$26.30 million||$25.50 million||View||Listen|
|7/29/2014||Q214||($0.09)||($0.07)||$23.40 million||$24.80 million||View||Listen|
|4/24/2014||Q1||($0.07)||($0.33)||$22.73 million||$20.80 million||View||Listen|
|2/6/2014||Q4||($0.10)||($0.17)||$21.01 million||$21.70 million||View||Listen|
|10/17/2013||Q313||($0.12)||($0.01)||$20.37 million||$21.60 million||View||Listen|
|8/1/2013||Q2 2013||($0.17)||($0.09)||$18.51 million||$19.60 million||View||Listen|
|4/23/2013||Q1 2013||($0.20)||($0.18)||$17.99 million||$17.90 million||View||Listen|
|3/1/2013||Q4 2012||($0.06)||($0.17)||$22.54 million||$21.14 million||View||N/A|
|11/1/2012||Q312||($0.26)||($0.19)||$20.43 million||$17.70 million||View||N/A|
AMAG Pharmaceuticals (NASDAQ:AMAG) Earnings Estimates
2018 EPS Consensus Estimate: ($3.97)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for AMAG Pharmaceuticals (NASDAQ:AMAG)
No dividend announcements for this company have been tracked by MarketBeat.com
AMAG Pharmaceuticals (NASDAQ AMAG) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.80%
AMAG Pharmaceuticals (NASDAQ AMAG) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/6/2018||Joseph Vittiglio||EVP||Sell||770||$20.80||$16,016.00||32,635|| |
|8/29/2017||Joseph Vittiglio||SVP||Sell||1,250||$16.75||$20,937.50||33,504|| |
|7/13/2017||Julie Krop||SVP||Sell||4,938||$20.00||$98,760.00||28,336|| |
|5/1/2017||Julie Krop||SVP||Sell||1,891||$24.45||$46,234.95||36,777|| |
|10/20/2016||Julie Krop||SVP||Sell||4,938||$24.80||$122,462.40||23,668|| |
|11/10/2015||John A Fallon||Director||Buy||3,230||$31.20||$100,776.00||6,086|| |
|10/1/2015||William K Heiden||CEO||Sell||2,000||$39.69||$79,380.00||200,721|| |
|9/1/2015||William K Heiden||CEO||Sell||2,000||$61.19||$122,380.00||202,721|| |
|7/15/2015||William K Heiden||CEO||Sell||20,000||$75.00||$1,500,000.00|| |
|6/15/2015||Scott A Holmes||SVP||Sell||7,580||$66.63||$505,055.40|| |
|6/5/2015||William K Heiden||CEO||Sell||66,875||$69.90||$4,674,562.50|| |
|6/4/2015||Frank E Thomas||COO||Sell||20,000||$69.47||$1,389,400.00|| |
|6/3/2015||Scott A Holmes||SVP||Sell||22,516||$68.88||$1,550,902.08|| |
|1/9/2015||Adage Capital Partners Gp Llc||Major Shareholder||Sell||1,250,000||$46.49||$58,112,500.00|| |
|1/9/2014||Christopher White||Insider||Sell||4,000||$22.37||$89,480.00||24,834|| |
|1/7/2014||Christopher White||Insider||Sell||5,000||$23.90||$119,500.00||28,834|| |
AMAG Pharmaceuticals (NASDAQ AMAG) News Headlines
|Form 8-K AMAG PHARMACEUTICALS For: Mar 23 - StreetInsider.com|
www.streetinsider.com - March 24 at 8:44 AM
|AMAG Pharmaceuticals Target of Unusually High Options Trading (AMAG)|
www.americanbankingnews.com - March 23 at 7:08 AM
|AMAG Pharmaceuticals, Inc. (AMAG) Given Average Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - March 18 at 1:50 PM
|AMAG Pharmaceuticals, Inc. (AMAG) Forecasted to Earn Q1 2018 Earnings of ($0.18) Per Share|
www.americanbankingnews.com - March 16 at 8:52 AM
|AMAG Pharmaceuticals (AMAG) PT Raised to $23.00|
www.americanbankingnews.com - March 14 at 5:27 PM
|Autodesk, SCANA, And 3 Other Stocks With Clear Trading Opportunities This Week|
www.benzinga.com - March 13 at 7:23 PM
|-$0.58 Earnings Per Share Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter|
www.americanbankingnews.com - March 12 at 1:44 PM
|AMAG Pharmaceuticals (AMAG) Cut to Hold at BidaskClub|
www.americanbankingnews.com - March 10 at 9:45 AM
|Form 4 AMAG PHARMACEUTICALS For: Mar 02 Filed by: Bolgiano Elizabeth Scott|
www.streetinsider.com - March 7 at 6:40 PM
|AMAG Pharmaceuticals, Inc. (AMAG) Expected to Post Q1 2018 Earnings of ($0.08) Per Share|
www.americanbankingnews.com - March 7 at 8:16 AM
|Antares Pharma: Building Momentum To 2018 Profitability - Antares ... - Seeking Alpha|
seekingalpha.com - March 7 at 8:11 AM
|AMAG Pharmaceuticals, Inc. (AMAG) EVP Joseph Vittiglio Sells 770 Shares|
www.americanbankingnews.com - March 6 at 9:58 PM
|Premarket analyst action - healthcare - AMAG Pharmaceuticals, Inc ... - Seeking Alpha|
seekingalpha.com - March 6 at 8:10 AM
|Jefferies Group Lowers AMAG Pharmaceuticals (AMAG) to Hold|
www.americanbankingnews.com - March 5 at 5:34 PM
|AMAG Pharmaceuticals to Present at Upcoming Investor Conferences|
finance.yahoo.com - March 5 at 8:12 AM
|Bogle Investment Management L P DE Acquires Shares of 328,455 AMAG Pharmaceuticals, Inc. (AMAG)|
www.americanbankingnews.com - March 4 at 4:58 AM
|AMAG Pharmaceuticals (AMAG) Upgraded to Buy by BidaskClub|
www.americanbankingnews.com - March 4 at 12:16 AM
|Spark Investment Management LLC Invests $1.55 Million in AMAG Pharmaceuticals, Inc. (AMAG) Stock|
www.americanbankingnews.com - March 3 at 12:36 PM
|Piper Jaffray Companies Reaffirms "Hold" Rating for AMAG Pharmaceuticals (AMAG)|
www.americanbankingnews.com - March 1 at 8:13 PM
|AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues - Nasdaq|
www.nasdaq.com - March 1 at 8:10 AM
|Systematic Financial Management LP Acquires 26,945 Shares of AMAG Pharmaceuticals, Inc. (AMAG)|
www.americanbankingnews.com - February 28 at 5:40 PM
|Morgan Stanley Boosts AMAG Pharmaceuticals (AMAG) Price Target to $24.00|
www.americanbankingnews.com - February 28 at 3:45 PM
|AMAG Pharmaceuticals (AMAG) CEO Bill Heiden on Q4 2017 ... - Seeking Alpha|
seekingalpha.com - February 28 at 8:12 AM
|Cowen Analysts Give AMAG Pharmaceuticals (AMAG) a $25.00 Price Target|
www.americanbankingnews.com - February 27 at 7:22 PM
|AMAG Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides|
seekingalpha.com - February 27 at 5:59 PM
|AMAG Pharmaceuticals tops Street 4Q forecasts|
finance.yahoo.com - February 27 at 5:59 PM
|AMAG Pharmaceuticals' (AMAG) "Hold" Rating Reiterated at Cantor Fitzgerald|
www.americanbankingnews.com - February 27 at 5:46 PM
|AMAG Pharmaceuticals (AMAG) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS|
www.americanbankingnews.com - February 27 at 5:14 PM
|AMAG Reports 2017 Financial Results and Company Update - GlobeNewswire (press release)|
globenewswire.com - February 27 at 8:13 AM
|AMAG Pharmaceuticals, Inc. to Host Earnings Call|
finance.yahoo.com - February 27 at 8:13 AM
|AMAG Reports 2017 Financial Results and Company Update|
finance.yahoo.com - February 27 at 8:13 AM
|Contrasting AMAG Pharmaceuticals (AMAG) & Impax Laboratories (IPXL)|
www.americanbankingnews.com - February 25 at 3:32 PM
|Zacks: Analysts Anticipate AMAG Pharmaceuticals, Inc. (AMAG) Will Announce Quarterly Sales of $157.24 Million|
www.americanbankingnews.com - February 25 at 4:24 AM
|AMAG Pharmaceuticals, Inc. (AMAG) Expected to Post Earnings of -$0.31 Per Share|
www.americanbankingnews.com - February 23 at 2:20 PM
|AMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Rating of "Hold" by Brokerages|
www.americanbankingnews.com - February 21 at 2:30 PM
|AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on ... - GlobeNewswire (press release)|
globenewswire.com - February 21 at 8:15 AM
|AMAG Pharmaceuticals (AMAG) Scheduled to Post Quarterly Earnings on Wednesday|
www.americanbankingnews.com - February 21 at 2:22 AM
|AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on Tuesday, February 27, 2018 at 8:00 a.m. ET|
finance.yahoo.com - February 20 at 5:51 PM
|AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on ... - Nasdaq|
www.nasdaq.com - February 20 at 8:12 AM
|Blog Exposure - FDA Granted Approval to AMAG’s Makena(R) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-risk Women|
finance.yahoo.com - February 20 at 8:12 AM
|AMAG Pharmaceuticals, Inc. Forecasted to Post FY2022 Earnings of ($0.44) Per Share (AMAG)|
www.americanbankingnews.com - February 19 at 9:34 AM
|AMAG Pharmaceuticals (AMAG) Upgraded to "Hold" by BidaskClub|
www.americanbankingnews.com - February 18 at 3:32 PM
|AMAG Pharmaceuticals, Inc. (AMAG) to Post FY2019 Earnings of ($2.19) Per Share, Cantor Fitzgerald Forecasts|
www.americanbankingnews.com - February 16 at 3:34 PM
|Why AMAG Pharmaceuticals Is Soaring - 24/7 Wall St.|
247wallst.com - February 16 at 8:13 AM
|Antares Pharma, Amag Pharma shares soar premarket after FDA approves auto injector - MarketWatch|
www.marketwatch.com - February 16 at 8:13 AM
|Why AMAG Pharmaceuticals, Inc. (AMAG) Shares Are Skyrocketing Today - Investorplace.com|
investorplace.com - February 16 at 8:13 AM
|Why AMAG Pharmaceuticals, Inc. and Antares Pharma, Inc. Are Soaring Today - Motley Fool|
www.fool.com - February 16 at 8:13 AM
|AMAG Pharmaceuticals Sees Unusually Large Options Volume (AMAG)|
www.americanbankingnews.com - February 16 at 6:38 AM
|This Biotech Stock Pops 30% On FDA Nod — 'Slamming Door' On Woes|
finance.yahoo.com - February 15 at 5:24 PM
|Cowen Drops Coverage on AMAG Pharmaceuticals (AMAG)|
www.americanbankingnews.com - February 15 at 5:06 PM
AMAG Pharmaceuticals (NASDAQ:AMAG) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AMAG Pharmaceuticals (NASDAQ:AMAG) Income Statement, Balance Sheet and Cash Flow Statement
AMAG Pharmaceuticals (NASDAQ AMAG) Stock Chart for Saturday, March, 24, 2018